That is 0 articles you have read today.
The Aporia is free and carries no advertising, so readers are the only
thing paying for it. If you are getting this much out of it, a small
donation is what keeps it independent.
Daily limit reached
You have read 0 articles today.
That is more than the 15 a day The Aporia gives away,
and well past what it can carry on nothing. Your allowance resets at
midnight.
There is no advertising here and nothing about you is sold, so readers
are the only thing paying for it. If the site is worth this much of
your day, it is worth a few dollars.
Everything else stays open: the
maps, the
directory and
search do
not count against this, and neither does re-opening something you have
already read today.
Eli Lilly’s experimental weight-loss drug, retatrutide, showed significant effectiveness in two studies published in The Lancet and the New England Journal of Medicine. Participants with Type 2 diabetes who took the highest dose lost an average of 18.8% of their body weight over a year and a half, compared to 5.1% for those on placebo. In a separate study focusing on overweight or obese individuals without diabetes, retatrutide led to a 25% weight loss in participants versus 3.9% for the placebo group. The drug’s unique mechanism of targeting three hormones—GLP-1, GIP, and glucagon—appears to offer greater benefits compared to existing medications, including improvements in diabetes control and reduced symptoms of osteoarthritis and sleep apnea.
Written locally by qwen2.5:14b on 2026-09-29,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
Eli Lilly's experimental drug retatrutide showed promising results for weight loss among people with Type 2 diabetes, according to studies published in The Lancet and New England Journal of Medicine. In one trial, participants taking the highest dose lost an average of 18.8% of their starting body weight over 1.5 years, compared to just 5.1% for those on placebo. Some patients lost up to 60 pounds (23%) of their initial weight, marking it as the most potent drug tested in diabetes care so far. Additionally, retatrutide not only aids significant weight loss but also improves blood sugar control; about 63% of participants lowered their A1C levels below 6.5%, which is indicative of better diabetes management. The drug's unique mechanism—targeting three hormone pathways instead of one or two—may contribute to its effectiveness compared to other GLP-1 drugs like Ozempic and Wegovy (semaglutide), as well as Mounjaro (tirzepatide).
Written for “Lilly Weight Loss Drug Trials” on 2026-10-08,
grounded in this article and the 2 other(s) covering the same event.
Two new studies published in separate journals show that an experimental drug developed by Eli Lilly leads to meaningful weight loss.
asserted
drug → publish → loss
One study, published in the Lancet and presented at the European Association for the Study of Diabetes, tested the drug retatrutide in people who were overweight or obese and had Type 2 diabetes: a population in which weight-loss medications have historically been less effective.
asserted
medications → publish → which
People who took the highest dose lost about 18.8% of their starting body weight, while people who took a placebo lost 5.1%.
asserted
who → take → %
About a third of the people in the study who took the highest dose of retatrutide lost at least 25% of their body weight, compared to 3% of those on placebo over the study period of 1.5 years.
asserted
who → take → years
“This is the most potent drug, showing the greatest percent weight loss in people with Type 2 diabetes with a pharmacological agent, shown to date,” says Dr. Juan Pablo Frias, medical director at the Los Angeles Institute for Metabolic Research and one of the Lancet study authors.
asserted
Frias → show → authors
People in the study also showed improvement in their diabetes control.
asserted
People → show → control
Of those who took the highest dose, 63% lowered their A1C to less than 6.5%—the threshold for diabetes—and lost at least 10% of their body weight.
asserted
% → take → weight
In another study published in the New England Journal of Medicine, researchers reported similar weight-loss benefits in people who were overweight or obese but who did not have diabetes.
asserted
who → publish → diabetes
In that study, people who took the highest dose of retatrutide lost about 25% of their starting body weight, while just 3.9% of people who took a placebo did the same.
asserted
who → take → same
People taking the drug were also studied for other benefits; those with osteoarthritis in the knee reported lower pain scores than those on placebo, while people with obstructive sleep apnea also reported fewer apnea episodes than those taking placebo.
asserted
people → take → placebo
Retatrutide targets three weight-related hormones: GLP-1, GIP, and glucagon.
asserted
Retatrutide → target → hormones
Since each has specific receptors in the body and brain, targeting all three may be contributing to the more potent effects on weight for people with diabetes than drugs that target GLP-1 alone, like Ozempic and Wegovy (semaglutide), or GLP-1 and GIP together, as Mounjaro and Zepbound (tirzepatide) do.
uncertain
Mounjaro → have → Ozempic
Zepbound is approved to not only control weight but to also treat obstructive sleep apnea, and Wegovy and Ozempic are approved to reduce the risk of heart disease.
asserted
Wegovy → approve → disease
In both studies, the side effects among people taking retatrutide were similar to those that have been reported with other GLP-1 medications, including GI issues such as abdominal cramps, nausea, vomiting, and diarrhea.
asserted
that → take → cramps
Eli Lilly says it plans to submit a request in early 2027 to the U.S. Food and Drug Administration to approve retatrutide based on these results.
asserted
it → say → results
The Aporia
